With four months in a row seeing spending reach over $2 million, Paraquat has now surpassed Mesothelioma for the first time since this mass tort hit the market! Paraquat campaign spending only continues to increase, a pattern we may continue to see through the end of the year.
CPA: $1,350 CPL: $475
Criteria: Diagnosis of Parkinson’s or experiencing Parkinson’s-like symptoms after being exposed to paraquat.
Zantac® has taken a few dips over the past few months. We are keeping an eye on spending this upcoming month, as the trial begins on October 10th. Check back with next month’s report to see where Zantac® will land!
CPA: $1,500 CPL: $600
Criteria: Took Zantac® for at least 4 months, diagnosed with stomach, bladder, kidney, pancreatic, esophageal, intestinal, liver, uterine, or colon cancer within 5 years of taking Zantac®.